Research programme: antibacterials - Elitra/Merck & Co
Alternative Names: Antibacterials research programme - Elitra/Merck & CoLatest Information Update: 04 Mar 2008
At a glance
- Originator Elitra Pharmaceuticals (CEASED); Merck & Co
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 20 May 2004 This programme is still in active development
- 05 Nov 2001 Preclinical development for Bacterial infections in USA (Unknown route)